By Deena Beasley SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in ...

A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...

The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

The drugmaker said it has started selling higher doses of the injectable treatment for $349 a month to patients paying the full bill.

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter, but management reduced 2025 guidance to 8%-14% sales growth and 10%-16% operating ...

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster ...

Novo Nordisk said it paused hiring in noncritical areas, as the Danish drugmaker seeks to tighten cost controls amid challenges in the obesity-drug market. The move comes shortly after Maziar Mike ...